Entergy Corp (ETR) 80.67 $ETR Entergy Corporation (ETR)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Entergy Corp (ETR) 80.67 $ETR

Entergy Corporation (ETR) Tops Q2 Earnings, Revises View
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 8:58AM CDT
Entergy Corporation (ETR) reported second-quarter 2016 operational earnings of $3.11 per share, beating the Zacks Consensus Estimate of $1.03 by 201.9%.
ETR: 80.67 (+0.31), PCG: 64.63 (+0.30), PEG: 44.92 (-0.24), DTE: 97.30 (-0.84)

Corporate Directors From Denny's, Nationwide, Office Depot, ONEOK, and Sempra Energy Become NACD Fellows in Q2 2016
GlobeNewswire - Tue Aug 02, 8:00AM CDT
The National Association of Corporate Directors (NACD), the advocate for the profession of directorship, today announced 111 corporate directors who earned NACD Fellowship--The Gold Standard Director Credential--during the second quarter of 2016. These corporate directors serve on the boards of companies such as Ace Hardware Corp., Blue Cross Blue Shield, Ciena Corp., Denny's Corp., Entergy Corp., Junior Achievement Worldwide, Lennox International Inc., Nationwide, Office Depot Inc., ONEOK Inc., Orbital ATK Inc., Pepco Holdings Inc., Sempra Energy, Tractor Supply Co., and on the corporate boards of other Fortune 500, nonprofit, and private companies.
TSCO: 90.76 (+0.46), ETR: 80.67 (+0.31), POM: 26.93 (+5.69), LII: 154.54 (-0.53), OKE: 44.15 (+0.21), ODP: 3.45 (+0.16), SRE: 110.69 (-0.10), OA: 86.75 (+0.53), DENN: 10.97 (+0.03)

Entergy Corporation (ETR) Beats on Q2 Earnings Estimates
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 7:26AM CDT
Entergy Corporation (ETR) reported second-quarter 2016 operational earnings of $3.11 per share, beating the Zacks Consensus Estimate of $1.03
ETR: 80.67 (+0.31)

Entergy Reports Second Quarter Earnings
PR Newswire - Tue Aug 02, 5:30AM CDT
Entergy Corporation (NYSE: ETR) reported second quarter 2016 earnings per share of $3.16 on an as-reported basis and $3.11 on an operational basis.
ETR: 80.67 (+0.31)

Sempra Energy (SRE) Q2 Earnings: Stock to Disappoint?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 10:37AM CDT
Sempra Energy (SRE) will report second-quarter 2016 earnings results before the opening bell on Aug 4. Let's see how things are shaping up for the second quarter.
ETR: 80.67 (+0.31), AES: 12.42 (+0.24), AVA: 42.82 (-0.36), SRE: 110.69 (-0.10)

Duke Energy (DUK): Stock to Beat Q2 Earnings Estimates?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 10:29AM CDT
Duke Energy Corp. (DUK), an electric and natural gas utility based in Charlotte, NC, is set to report second-quarter 2016 results before the opening bell on Aug 4. Let's see how things are shaping up for this quarter.
ETR: 80.67 (+0.31), AES: 12.42 (+0.24), AVA: 42.82 (-0.36), DUK: 85.34 (-0.22)

Utility Stocks' Q2 Earnings on Aug 2: ETR,NI, PNW, WR
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 8:36AM CDT
The steady drop in unemployment rates should further boost results of the Utility sector
ETR: 80.67 (+0.31), WR: 55.16 (-0.37), NI: 25.59 (-0.35), PNW: 78.44 (-0.34)

Why Entergy Corporation (ETR) Might Surprise This Earnings Season
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 7:33AM CDT
Entergy Corporation has earnings coming up pretty soon and events are shaping up quite nicely for its report.
ETR: 80.67 (+0.31)

Entergy Declares Dividend
PR Newswire - Fri Jul 29, 12:53PM CDT
The Board of Directors of Entergy Corporation (NYSE:ETR) has declared a quarterly dividend of $0.85 per common share. The payment date is September 1, 2016, to stockholders of record on August 11, 2016.
ETR: 80.67 (+0.31)

Correction: Powering New York's Future story
By DAVID KLEPPER - AP - Thu Jul 28, 12:44PM CDT
ALBANY, N.Y. (AP) — In a story July 27 about energy proposals in New York, The Associated Press misidentified the name of an environmental organization. It is the Natural Resources Defense Council, not the National Resources Defense Council.
ETR: 80.67 (+0.31), EXC: 36.83 (+0.05), EXCU: 50.05 (-0.15)

Entergy (ETR) Q2 Earnings: Will the Stock Beat Estimates?
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 7:08AM CDT
Entergy Corporation (ETR) will release second-quarter 2016 financial results before the opening bell on Aug 2.
ETR: 80.67 (+0.31), AES: 12.42 (+0.24), AVA: 42.82 (-0.36), PEGI: 24.06 (+0.24)

Entergy May Sell FitzPatrick Plant to Exelon: Here's Why
Zacks Equity Research - Zacks Investment Research - Thu Jul 14, 8:53AM CDT
Entergy Corporation (ETR) is currently in talks with Exelon Corporation (EXC) regarding a potential sale of its James A. FitzPatrick nuclear power plant in Scriba, NY
ETR: 80.67 (+0.31), EXC: 36.83 (+0.05), BKH: 63.07 (-0.02), LNT: 40.35 (-0.07)


Negotiators aim for sale to keep FitzPatrick nuke plant open
By MICHAEL HILL - AP - Wed Jul 13, 10:07AM CDT
ALBANY, N.Y. (AP) — Negotiations to save the FitzPatrick nuclear power plant from closure by selling it to the operators of a nearby nuclear plant on Lake Ontario are underway.
ETR: 80.67 (+0.31)

Entergy in Discussions for the Potential Sale of the James A. FitzPatrick Nuclear Power Plant to Exelon
PR Newswire - Wed Jul 13, 6:03AM CDT
Entergy Corporation (NYSE: ETR) announced today that it is in discussions with Exelon Corporation (NYSE: EXC) for the potential sale of the James A. FitzPatrick Nuclear Power Plant in Scriba, NY.
ETR: 80.67 (+0.31), EXC: 36.83 (+0.05)

Entergy Falls 1.68% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Jul 07, 2:05PM CDT
Entergy (NYSE:ETR) traded in a range yesterday that spanned from a low of $80.40 to a high of $82.01. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $80.56 on volume of 451,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ETR: 80.67 (+0.31)

Entergy (ETR) Veers Away from Merchant to Focus on Utility
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 2:22PM CDT
Entergy is gradually transforming itself from a hybrid to a pure-play utility. Foremost on its agenda is to lower its exposure to the risk-prone and volatile wholesale commodities market by scaling down its EWC business.
ETR: 80.67 (+0.31), AGR: 44.79 (-0.20), CNP: 23.52 (+0.05), SPKE: 24.50 (+0.12)

PG&E Corporation to Close Last Nuclear Plant in California
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 8:44AM CDT
PG&E Corporation (PCG) reached an agreement with environmental and labor groups to shut down California's last nuclear plant, Diablo Canyon.
ETR: 80.67 (+0.31), AGR: 44.79 (-0.20), PCG: 64.63 (+0.30), EXC: 36.83 (+0.05)

Entergy (ETR) Unit Back to Service after Planned Outage
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 9:50AM CDT
Entergy Corporation's (ETR) Indian Point Unit 2 nuclear plant has returned to service after a $120 million planned refueling outage.
ETR: 80.67 (+0.31), AGR: 44.79 (-0.20), EXC: 36.83 (+0.05), SPKE: 24.50 (+0.12)

Watch for Entergy to Potentially Rebound After Falling 1.19% Yesterday
Comtex SmarTrend(R) - Wed Jun 15, 1:29PM CDT
Entergy (NYSE:ETR) traded in a range yesterday that spanned from a low of $78.07 to a high of $78.99. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $78.16 on volume of 436,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ETR: 80.67 (+0.31)

After Yesterday's Decline of 1.19%, Entergy Offers Investors Better Value
Comtex SmarTrend(R) - Wed Jun 15, 1:27PM CDT
Entergy (NYSE:ETR) traded in a range yesterday that spanned from a low of $78.07 to a high of $78.99. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $78.16 on volume of 436,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ETR: 80.67 (+0.31)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 399

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 448

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 72

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 0

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 14

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 412

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 89

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

O-I Glass Announces Participation in Citi’s 2025 Conference

Updated Category News Views 208

O-I Glass Participation in the 2025 Basic Materials Conference PERRYSBURG, Ohio — O-I Glass, Inc., known for its commitment to creating exceptional glass products, is set to participate in the upcoming Citi’s 2025 Basic Materials Conference. This significant event will take place on a Wednesday in December, and features notable presentations from O-I's leadership....

Continue Reading
Osmium Partners Proposes Strategic Plan for Articore Growth

Updated Category News Views 104

Osmium Partners Proposes a Four-Step Plan for Articore Osmium Partners has recently made headlines with their proposal for Articore, aiming to elevate shareholder value through a methodical four-step approach. This initiative is driven by Osmium's belief that Articore's current management strategy lacks direction and has resulted in missed opportunities for growth and...

Continue Reading
Amplify Energy Set to Shine at EnerCom Denver Conference 2025

Updated Category News Views 135

Amplify Energy’s Participation in EnerCom Denver Conference Amplify Energy Corp. is gearing up to participate in the renowned annual EnerCom Denver Conference in 2025. This event, known for bringing together leading experts and investors in the energy sector, offers Amplify a prime platform to showcase its strategic initiatives and growth potential. Focus on Investor...

Continue Reading
Safe Life Expands CPR Training and AED Services through Acquisition

Updated Category News Views 197

Safe Life Strengthens National Coverage for Life-Saving Training Safe Life has made a significant move by acquiring HeartCert, a company known for its specialization in automated external defibrillators (AEDs) and CPR training. This acquisition allows Safe Life to broaden its reach into the Midwest, enhancing its commitment to providing life-saving training and equipment...

Continue Reading
Express Scripts Challenges FTC's Drug Pricing Conclusions

Updated Category News Views 106

Express Scripts Files Lawsuit Against the FTC Express Scripts, a major player in the pharmacy benefit manager sector, has recently taken legal action against the U.S. Federal Trade Commission (FTC). This lawsuit stems from a report that criticizes the role of pharmacy benefit managers in the pricing of medications. Express Scripts contends that the report's conclusions...

Continue Reading